The privately-held European mid-sized pharmaceutical company Chiesi Farmaceutici SPA is hoping an orally active small molecule being developed by acquisition target Atopix Therapeutics Ltd. for eosinophilic asthma will trump the more advanced injectable monoclonal antibodies in development for the condition, or already marketed by competitors.
Chiesi is to acquire the UK based Atopix for an amount that could exceed €75m ($80m), the Parma, Italy-based company...








